Monday, July 21, 2014

Advances in chemo have lengthened non-small cell lung cancer survival

YouTube courtesy The Oncology Channel spon-
sored by Boehringer Ingelheim
CANCER DIGEST – July 21, 2014 – Patients with advanced non-small cell lung cancer survived significantly longer when treated with second and third line chemotherapy compared to patients who did not receive any chemotherapy, a new analysis of patient survival shows.

The researchers from the British Columbia Cancer Agency, Vancouver, Canada analyzed
the survival outcomes of 2,606 lung cancer patients treated from 1998 to 2008 outside of clinical trials. They grouped them into four sets based on the introduction of different chemotherapy agents that became commercially available during the study period. 

The median overall survival of the patients who did not receive any chemotherapy did not change significantly over the four time points: 3.9, 4.0, 3.1 and 3.2 months. Over those four periods however for those that did receive chemotherapy, survival increased significantly for each of the four periods 9.4. 9.8 11.0 and 11.8 months. 

Overall for all the 2,606 patients, survival ranged from a median of 3.5 months for those who received no chemotherapy to 17 months for those receiving second- or third-line chemotherapy. The results will be published in the August Issue of the Journal of Thoracic Oncology.

No comments:

Post a Comment